Integra LifeSciences Holdings (IART)
Debt-to-capital ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 1,395,820 | 1,300,490 | 1,388,680 | 1,408,220 | 1,198,560 |
| Total stockholders’ equity | US$ in thousands | 1,587,880 | 1,804,400 | 1,684,800 | 1,514,870 | 1,416,740 |
| Debt-to-capital ratio | 0.47 | 0.42 | 0.45 | 0.48 | 0.46 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,395,820K ÷ ($1,395,820K + $1,587,880K)
= 0.47
The debt-to-capital ratio of Integra Lifesciences Holdings Corp has fluctuated over the past five years. In 2023, the ratio increased to 0.49 from 0.44 in 2022, indicating that the company's level of debt relative to its total capital also increased. This implies that a larger portion of the company's capital structure is composed of debt in 2023 compared to the previous year.
The ratio was relatively stable around the 0.48 to 0.51 range in the preceding three years (2021, 2020, and 2019), suggesting a consistent proportion of debt in relation to the total capital structure during that period.
Overall, monitoring changes in the debt-to-capital ratio is important for assessing the financial risk and leverage of Integra Lifesciences Holdings Corp. An increasing ratio may indicate higher financial risk, as a larger proportion of the company's capital is funded by debt, which could lead to increased interest expenses and potential challenges in servicing the debt obligations.
Peer comparison
Dec 31, 2023